Moreover, GLI1 (GANT61) but not SMO (GDC-0449 and LDE225) inhibition significantly reduced FOXC1-induced GLI-BS-luciferase activity in both SMO-positive and SMO-negative breast cancer cell lines, suggesting an SMO-independent activation of GLI [116]. Here, SMO is linked to breast carcinoma.